GRI Bio

GRI Bio EBITDA Margin

The EBITDA Margin of GRI Bio (GRI) as of Nov 2, 2026 is -36.54 %. In the previous year, EBITDA Margin was -50.33 % — a change of -27.40% (higher).

EBITDA Margin

-36.54 %

YoY

-27.40%

Last updated:

EBITDA Margin of GRI Bio is 2024 -36.54 % . EBITDA Margin of GRI Bio was 2023 -50.33 % . It decreases by -27.40% higher compared to the previous year.

The GRI Bio EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2020
-1,459.00 USD
Jan 1, 2023
-50.33 USD
Jan 1, 2024
-36.54 USD
The GRI Bio EBITDA Margin history
YEAREBITDA MarginYoY
-36.54 %-27.40%
-50.33 %-96.55%
-1,459.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GRI Bio Stock analysis

What does GRI Bio do? GRI Bio, Inc. generates revenue through the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company focuses on advancing a pipeline of Natural Killer T (NKT) modulating therapies, including its lead program GRI-0621, a small molecule RAR-beta dual agonist for Idiopathic pulmonary fibrosis (IPF) treatment. GRI-0621 is formulated as a once-daily oral capsule targeting multiple fibrotic indications. The firm also develops GRI-0803, a novel activator of human Type 2 NKT cells for autoimmune disorders, initially targeting systemic lupus erythematosus. Additionally, GRI Bio holds a library of 500+ proprietary compounds addressing high-value indications with unmet medical needs. GRI Bio's primary customers are pharmaceutical companies and healthcare providers seeking innovative treatments for complex diseases. The company's lead asset GRI-0621 is positioned for clinical development in IPF, while GRI-0803 targets systemic lupus erythematosus. The firm's proprietary compound library supports potential partnerships and licensing agreements for high-value therapeutic areas. The company's business model relies on advancing its pipeline through clinical trials and securing strategic collaborations for drug development and commercialization. The company's revenue streams include potential licensing fees from pharmaceutical partners, milestone payments upon achieving clinical or regulatory milestones, and future royalties from commercialized products. GRI Bio's focus on NKT modulating therapies for inflammatory, fibrotic, and autoimmune diseases positions it to address significant unmet medical needs in these therapeutic areas. The firm's pipeline includes GRI-0621 for IPF and GRI-0803 for systemic lupus erythematosus, with additional compounds targeting other high-value indications. GRI Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GRI Bio stock

EBITDA Margin of GRI Bio is -36.54 % in 2024.

EBITDA Margin of GRI Bio changed from -50.33 % to -36.54 %, representing a -27.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin GRI Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's GRI Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — GRI Bio

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — GRI Bio